Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Compass Therapeutics
Mayo Clinic
ViroMissile, Inc.
Eisai Inc.
Children's Oncology Group
Seagen Inc.
SEED Therapeutics, Inc.
Essen Biotech
DualityBio Inc.
Jonsson Comprehensive Cancer Center
MacroGenics
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
M.D. Anderson Cancer Center
Mayo Clinic
University of Pittsburgh
GV20 Therapeutics
NeoTX Therapeutics Ltd.
West China Hospital
DualityBio Inc.
Sotio Biotech Inc.
National Institutes of Health Clinical Center (CC)
University of Pittsburgh
Incyte Corporation
Pfizer
GONGCHU Biotechnology Co., Ltd
Exelixis
Incyte Corporation
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Cancer Research UK
University of Virginia
Incyte Corporation
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
UNICANCER
HC Biopharma Inc.
Sotio Biotech Inc.
Carisma Therapeutics Inc
Tasly Biopharmaceuticals Co., Ltd.
Molecular Templates, Inc.
Salubris Biotherapeutics Inc
Xencor, Inc.
Pliant Therapeutics, Inc.
Exelixis
National Cancer Institute (NCI)
ImmVira Pharma Co. Ltd
BioEclipse Therapeutics